LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) and PharmaCyte Biotech (OTCMKTS:PMCBD – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk. Earnings and Valuation This table compares LENZ […]
LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) and PharmaCyte Biotech (OTCMKTS:PMCBD – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation. Insider & Institutional Ownership 54.3% of LENZ […]
Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value
.
Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front
.
MyMD Pharmaceuticals Secures Strategic Investments Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an.